08th week of 2016 patent applcation highlights part 22 |
Patent application number | Title | Published |
20160052949 | HYDROXIDE CATALYSTS FOR LIGNIN DEPOLYMERIZATION - Solid base catalysts and their use for the base-catalyzed depolymerization (BCD) of lignin to compounds such as aromatics are presented herein. Exemplary catalysts include layered double hydroxides (LDHs) as recyclable, heterogeneous catalysts for BCD of lignin. | 2016-02-25 |
20160052950 | NOVEL PROCESS FOR PREPARING POLYOL GLYCOSIDES - A process for preparing a composition (C | 2016-02-25 |
20160052951 | MACROLIDES AND METHODS OF THEIR PREPARATION AND USE - Provided herein are methods of preparing macrolides by the coupling of an eastern and western half, followed by macrocyclization, to provide macrolides, including both known and novel macrolides. Intermediates in the synthesis of macrolides including the eastern and western halves are also provided. Pharmaceutical compositions and methods of treating infectious diseases and inflammatory conditions using the inventive macrolides are also provided. A general diastereoselective aldol methodology used in the synthesis of the western half is further provided. | 2016-02-25 |
20160052952 | SUBSTITUTED GEMCITABINE BICYCLIC AMIDE ANALOGS AND TREATMENT METHODS USING SAME - In one aspect, the invention relates to substituted gemcitabine aryl amide analogs, derivatives thereof, and related compounds; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating viral disorders and disorders of uncontrolled cellular proliferation using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2016-02-25 |
20160052953 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES - Provided herein are formulations, methods and substituted 2′-chloro aminopyrimidinone and pyrimidine dione compounds of Formula (I) for treating Pneumovirinae virus infections, including respiratory syncytial virus infections, as well as methods and intermediates for synthesis of substituted 2′-chloro aminopyrimidinone and pyrimidine dione compounds. | 2016-02-25 |
20160052954 | COMPOUNDS AND METHODS ASSOCIATED WITH DIFFERENTIAL METHYLATION OF HUMAN PAPILLOMA VIRUS GENOMES IN EPITHELIAL CELLS - The invention relates to compounds and methods useful in detection and therapy of HPV-associated diseases. The invention is based on the elucidation of a mechanism by which replication of HPVs occurs in naturally infected tissues and cells. Moreover it is based on the identification of distinct epigenetic changes of the viral genome in infected cells that allows promotion of the affected cells to precancerous and cancerous cells. The invention therefore provides methods of diagnosing neoplasias and their precursor lesions as well as methods of preventing the development of malignancies or inhibiting tumor growth. | 2016-02-25 |
20160052955 | METHYLTRANSFERASE INHIBITORS FOR TREATING CANCERS - Compounds having methyltransferase inhibitory activity are disclosed. The compounds have the structure | 2016-02-25 |
20160052956 | TGR5 MODULATORS AND METHODS OF USE THEREOF - The invention relates to compounds of Formula A: | 2016-02-25 |
20160052957 | PROGESTERONE ANALOGS AND USES RELATED THERETO - This disclosure relates to progesterone derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation resulting from traumatic brain injury or stroke. | 2016-02-25 |
20160052958 | PROCESS FOR THE PURIFICATION OF ABIRATERONE ACETATE - The invention relates to a process for the purification of crude abiraterone acetate by treatment with polymer resins in aqueous solvent. The purified product is recovered by simple concentration and filtration. | 2016-02-25 |
20160052959 | RADIOLABELED CATIONIC STEROID ANTIMICROBIALS AND DIAGNOSTIC METHODS - The disclosure provides compounds, methods, and kits for diagnosis, detection, screening, and imaging of a disease condition (e.g., infection, cancer, tumor, neoplasia), in vitro, ex vivo, and/or in vivo. Certain embodiments include administering a cationic steroid antimicrobial “CSA” or “ceragenin”), the CSA including a steroidal backbone and a heterocyclic ring separated from the steroidal backbone by at least 4 atoms (and up to 24 atoms or more), to a subject having or at risk of having a disease condition in an amount effective to diagnose, detect, screen for or image the disease condition in the subject. | 2016-02-25 |
20160052960 | PROCESS FOR THE PREPARATION OF DROSPIRENONE - A process is disclosed wherein, using either 17a-(3-hydroxypropyl)-6p,7p;15p,16p-dimethylene-5p-androstane-3p,5,17p-triol (II) or 3β,5̂iÎκ̂-6β,7β;15β,16β-dimethylene-5β,17α-pregnane-21,17-carbolactone (III) as starting material, through a single-step reaction it is obtained drospirenone (I), a synthetic steroid with progestogenic, antimineralocorticoid and antiandrogenic activity, useful for preparing pharmaceutical compositions with contraceptive action. | 2016-02-25 |
20160052961 | SURFACE NEUTRALIZATION OF APATITE - The present invention discloses methods of neutralizing apatite surfaces, for example during chromatography and before protein elution. | 2016-02-25 |
20160052962 | METHOD FOR ISOLATING COLLAGEN FROM JELLYFISH BY USING RADIATION - The present invention relates to a method for separating collagen from jellyfish by using radiation. More precisely, acid-soluble collagen and attelo collagen were prepared in this invention by using the method combining irradiation technique and chemical treatment. This method of the invention is expected to be useful for the separation of collagen from jellyfish with low costs but high yield. | 2016-02-25 |
20160052963 | PROCESS FOR PURIFICATION OF A FATTY ACID BINDING PROTEIN - A process for purification of a fatty acid binding proteins such as, e.g., Sm14 of | 2016-02-25 |
20160052964 | METHODS AND COMPOSITIONS USING ADAM10 INHIBITORS TO TREAT BACTERIAL INFECTIONS - Certain embodiments are directed to compositions and methods of inhibiting a pathogenic bacterial infection involving ADAM10, specifically a method for treating pore-forming toxin-inducted pathology caused by exposure to | 2016-02-25 |
20160052965 | Dimeric IAP Inhibitors - Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language | 2016-02-25 |
20160052966 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acid Linked Dolastatin Derivatives - Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use. | 2016-02-25 |
20160052967 | USE OF INHIBITORY PEPTIDES FOR THE TREATMENT OF INFLAMMATORY DISEASES - An isolated peptide is disclosed which comprises an amino acid sequence being at least 80% homologous to the sequence as set forth in SEQ ID NO: 1 (PERYQNLSPV), the isolated peptide comprising a nuclear targeting activity, the peptide being no longer than 20 amino acids. | 2016-02-25 |
20160052968 | BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE - A bone delivery conjugate having a structure selected from the group consisting of: A) X-D | 2016-02-25 |
20160052969 | TEMPLATES FOR CONTROLLING SYNTHESIS OF NANOPARTICLES INTO DISCRETE ASSEMBLIES - An approach to synthesizing and assembling nanoparticles into discrete, size-tunable, pre-designed architectures is realized in a single synthetic/process step. | 2016-02-25 |
20160052970 | PEPTIDOMIMETIC MACROCYCLES AND USE THEREOF IN REGULATING HIF1ALPHA - The present invention provides peptidomimetic macrocycles capable of regulating HIF1α and methods of using such macrocycles for the treatment of diseases. | 2016-02-25 |
20160052971 | BETA-HAIRPIN PEPTIDOMIMETICS - Beta-hairpin peptidomimetics of the general formula (I), cyclo[P | 2016-02-25 |
20160052972 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION - The present invention relates to a compound of the formula (I): | 2016-02-25 |
20160052973 | Stabilised FMDV Capsids - The present invention relates to the stabilisation of foot-and-mouth disease virus (FMDV) capsids, by specific substitution of amino acids in a specific region of FMDV VP2. The invention provides stabilised FMDV capsids and vaccines against FMD. | 2016-02-25 |
20160052974 | NOVEL GENES AND PROTEINS OF BRACHYSPIRA HYODYSENTERIAE AND USES THEREOF - Novel polynucleotide and amino acids of | 2016-02-25 |
20160052975 | Recombinant polypeptide construct comprising multiple enterotoxigenic Escherichia coli fimbrial subunits - The inventive subject matter relates to a recombinant polypeptide construct comprising enterotoxigenic | 2016-02-25 |
20160052976 | MODIFIED MICROBIAL TOXIN RECEPTOR FOR DELIVERING AGENTS INTO CELLS - We described a novel system of targeted cell therapy with a protein toxin, such as anthrax toxin, that has been modified to re-direct it to a desired cell target instead of its natural cell target. The system can be used for, e.g., targeted killing of undesired cells in a population of cells, such as cancer or overly active immune system cells. | 2016-02-25 |
20160052977 | NOVEL TOXINS IN TYPE A CLOSTRIDIUM PERFRINGENS - The present disclosure relates to novel pore-forming toxins of Type A | 2016-02-25 |
20160052978 | ANTIMICROBIAL PROTEIN - The inventors provide a composition comprising an antimicrobial polypeptide comprising Blad or an active variant thereof for use in a method of treatment of the human or animal body by therapy or prophylaxis, such as for use in a method of treating or preventing an infection in or on a subject by a microorganism. Also provided is the use of a composition comprising an antimicrobial polypeptide comprising Blad or an active variant thereof to kill, or inhibit the growth of, a microorganism that is pathogenic to a human or an animal at a site that is not on or in the human or animal body. | 2016-02-25 |
20160052979 | FAMILY OF SYNTHETIC POLYNUCLEOTIDE-BINDING PEPTIDES AND USES THEREOF - The present invention provides novel synthetic peptides (including the TZIP peptide) as oncogenic and genetic modulators, including genetics of viruses, as well as methods of making and using the same. These peptides are useful for inhibiting the proliferation of cancer cells characterized as having amplified c-MYC genes. The invention provides methods for the therapeutic uses of the peptides in the treatment of various cancers including small cell lung carcinoma, prostate cancer, lymphoma, brain tumors, colon cancer, bladder cancer, AML, malignant melanoma, mesothelioma, and cancers of head and neck. The peptides are also useful in the treatment of and prevention of transmission of HIV and treatment of expanded nucleotide repeat diseases, including certain currently untreatable and debilitating diseases. | 2016-02-25 |
20160052980 | CRP40 FRAGMENTS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - Disclosed herein are human CRP40 fragments and polynucleotides encoding them. The CRP40 fragments and polynucleotides may be useful in the treatment of diseases associated with one or more of oxidative stress, mitochondrial dysfunction and abnormal protein folding, including various neurological disorders. | 2016-02-25 |
20160052981 | REGULATORS OF NFAT - Disclosed are methods of identifying an agent that modulates an NFAT regulator protein. One such method comprises contacting at least one test agent with recombinant cell comprising at least one NFAT regulator protein or fragment or derivative thereof, assessing the effect of the test agent on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, and identifying the test agent that has an effect on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, whereby the identified test agent is characterized as an agent that modulates an NFAT regulator protein. Methods of identifying an agent that modulates intracellular calcium, methods to screen for an agent that modulates NFAT regulator function, methods to diagnose unexplained immunodeficiency in a subject, and methods for identifying an agent for treating or preventing a disease or disorder associated with a NFAT regulator protein or calcium signaling are also disclosed. | 2016-02-25 |
20160052982 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS - The present application provides methods for preparing soluble lipidated ligand agents comprising a ligand entity and a lipid entity, and in some embodiments, provides relevant parameters of each of these components, thereby enabling appropriate selection of components to assemble active agents for any given target of interest. | 2016-02-25 |
20160052983 | Fusion Polypeptides Comprising an Active Protein Linked to a Mucin-Domain Polypeptide - The present invention provides fusion proteins comprising a mucin-domain polypeptide covalently linked to an active protein that has improved properties (e.g. pharmacokinetic and/or physicochemical properties) compared to the same active protein not linked to mucin-domain polypeptide, as well as methods for making and using the fusion proteins of the invention. | 2016-02-25 |
20160052984 | OSTEOGENIC PROTEINS - The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics. | 2016-02-25 |
20160052985 | THYMIC STROMAL LYMPHOPOIETIN FRAGMENTS AND USES THEREOF - The present invention relates to a compound selected in the group consisting of: a) a polypeptide consisting of the C-terminus amino acid sequence of the human Thymic stromal lymphopoietin (TSLP) long isoform (SEQ ID NO: 2), derivatives and fragments thereof; b) a polynucleotide coding for said polypeptide; d) a vector comprising said polynucleotide; c) a host cell genetically engineered expressing said polypeptide, or d) a TSLP long isoform (SEQ ID NO:2) antagonist for use in the treatment or/and prevention and/or diagnosis and/or monitoring of a disorder or pathology characterized by an inflammatory response. | 2016-02-25 |
20160052986 | HUMANIZED IL-7 RODENTS - Genetically modified non-human animals comprising a human or humanized interleukin-7 (IL-7) gene. Cells, embryos, and non-human animals comprising a human or humanized IL-7 gene. Rodents that express human or humanized IL-7 protein. Genetically modified mice that comprise a human or humanized IL-7-encoding gene in their germline, wherein the human or humanized IL-7-encoding gene is under control of endogenous mouse IL-7 regulatory sequences. | 2016-02-25 |
20160052987 | POLYPEPTIDE HAVING SIALYLATED SUGAR CHAINS ATTACHED THERETO - The object of the present invention is to provide a polypeptide having interferon β activity glycosylated with highly uniform sialylated sugar chains. The present invention is a glycosylated polypeptide, wherein the polypeptide is any polypeptide selected from the group consisting of the following (1) to (4); (1) a polypeptide consisting of the amino acid sequence represented by SEQ ID NO. 1, (2) a polypeptide having one or a few amino acids deleted, substituted, or added in the polypeptide consisting of the amino acid sequence represented by SEQ ID NO. 1, (3) a polypeptide that is an analog of interferon β, and (4) a polypeptide having 80% or more homology to the polypeptide consisting of the amino acid sequence represented by SEQ ID NO. 1, in which amino acids at 4 to 6 locations are substituted with glycosylated amino acids, and wherein all of the non-reducing terminals of said sugar chain are sialylated. | 2016-02-25 |
20160052988 | PEPTIDE COMPOUND - The present invention provides a novel peptide compound having an activating action on GLP-1 receptors and GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a partial sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. P | 2016-02-25 |
20160052989 | GIP RECEPTOR-ACTIVE GLUCAGON COMPOUNDS - Glucagon peptides with increased GIP activity are provided, optionally with GLP-1 and/or glucagon activity. In some embodiments, C-terminally extended glucagon peptides comprising an amino acid sequence substantially similar to native glucagon are provided herein. | 2016-02-25 |
20160052990 | HIGH AFFINITY PD-1 AGENTS AND METHODS OF USE - High affinity PD-1 mimic polypeptides are provided, which (i) comprise at least one amino acid change relative to a wild-type PD-1 protein; and (ii) have an increased affinity for PD-L1 relative to the wild-type protein. Compositions and methods are provided for modulating the activity of immune cells in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity PD-1 mimic polypeptide, which blocks the physiological binding interaction between PD-1 and its ligand PD-L1 and/or PD-L2. | 2016-02-25 |
20160052991 | MUTANT G-PROTEIN COUPLED RECEPTORS AND METHODS FOR SELECTING THEM - The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the mutant G-protein coupled receptors, and methods of preparing the same. | 2016-02-25 |
20160052992 | Kits for Isolating Protein Samples - Novel kits and methods for recovering nucleic acids and proteins from a biological sample having the steps of mixing a biological sample with a nucleic acid binding solution and contacting the mixture with a first porous silica compound configured to reversibly bind a nucleic acid are disclosed herein. The fluid remainder of the mixture is gathered for protein extraction. The first silica compound is contacted with a nucleic acid elution solution which causes a majority of the nucleic acid bound to the first porous silica compound to unbind and enter the solution phase. The solution is collected, which contains isolated nucleic acid. The fluid gathered for protein extraction is mixed with a protein binding solution and contacted with a protein binding porous silica compound configured to reversibly bind a protein. The fluid remainder is separated from the protein binding porous silica compound. A protein elution solution is contacted with the protein binding porous silica compound to cause a majority of the protein bound to the protein binding porous silica compound to unbind and enter the solution phase, allowing the protein to be isolated. | 2016-02-25 |
20160052993 | ALBUMIN VARIANTS BINDING TO FCRN - The invention relates to methods of identifying albumin variants having improved pharmacokinetics, albumin variants having improved pharmacokinetics, and therapeutic uses of albumin variants having improved pharmacokinetics. | 2016-02-25 |
20160052994 | MODIFIED LAMININ CONTAINING COLLAGEN BINDING MOLECULE AND USE THEREOF - A modified laminin characterized in that a laminin or a heterotrimeric laminin fragment has a collagen binding molecule conjugated to at least one site selected from the α chain N-terminus, the β chain N-terminus and the γ chain N-terminus, and an extracellular-matrix material comprising the modified laminin, and collagen and/or gelatin serve as an alternative to Matrigel and are useful as an extracellular-matrix material for the formation of a safe three-dimensional tissue structure for regenerative medicine in humans. | 2016-02-25 |
20160052995 | METHOD FOR ISOLATION OF SOLUBLE POLYPEPTIDES - Polypeptides with desirable biophysical properties such as solubility, stability, high expression, monomericity, binding specificity or non-aggregation, including monomeric human V | 2016-02-25 |
20160052996 | RECOMBINANT HUMAN ANTIBODIES FOR THERAPY AND PREVENTION OF POLYOMAVIRUS-RELATED DISEASES - Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of JC virus (JCV) and/or BK virus (BKV) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus VP1 and or polyomavirus VP1 Virus-Like Particles (VLPs), preferably of the type of JCV and/or BKV, are disclosed. The human-derived antibodies as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for polyomavirus targeted immunotherapy and diagnostics. | 2016-02-25 |
20160052997 | COMPOSITION COMPRISING AT LEAST TWO INFLUENZA A VIRUS-NEUTRALIZING-BINDING MOLECULES - The present invention provides a composition comprising at least two influenza A virus-neutralizing binding molecules that bind to an epitope in the stem region of influenza A virus hemagglutinin (HA) protein, the method comprising: i) a first binding molecule capable of neutralizing at least one influenza A virus subtype selected from the group consisting of H1, H2, H5 and H9; ii) a second binding molecule capable of neutralizing at least one influenza A virus subtype selected from the group consisting of H1, H3, H5, H7 and H9. The mixed composition of the present invention can effectively neutralize the multiple influenza subtypes of both phylogenetic group 1 and phylogenetic group 2 and can be used in combination with a chemical compound. Thus, the composition of the present invention is very useful for the prevention and treatment of a disease by influenza virus. | 2016-02-25 |
20160052998 | ANTI-SERUM ALBUMIN BINDING VARIANTS - The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts. | 2016-02-25 |
20160052999 | FUNCTIONAL HEAVY CHAIN ANTIBODIES, FRAGMENTS THEREOF, LIBRARY THEREOF AND METHODS OF PRODUCTION THEREOF - The present invention relates to functional heavy chain antibodies, functional single domain heavy chain antibodies, functional VH domains, or functional fragments thereof comprising an amino acid which is neither a charged amino acid nor a C at position 45, and comprising an amino acid at position 103 independently chosen from the group consisting of R, G, K, S, Q, L, and P, and optionally an amino acid at position 108 independently chosen from the group consisting of Q, L and R, said positions determined according to the Kabat numbering. | 2016-02-25 |
20160053000 | APELIN ANTIGEN-BINDING PROTEINS AND USES THEREOF - This disclosure relates to apelin antigen-binding proteins and methods of using the apelin antigen-binding proteins. The antigen-binding protein may comprise an antibody to apelin and can be used to treat pathological conditions involving angiogenesis. The pathological conditions can comprise cancer or retinopathy and/or retinopathy-related complications. | 2016-02-25 |
20160053001 | DIAGNOSTIC ANTIBODY ASSAY - Novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided. | 2016-02-25 |
20160053002 | ANTI-COMPLEMENT C1S ANTIBODIES AND USES THEREOF - The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions. | 2016-02-25 |
20160053003 | COMPOSITIONS AND METHODS FOR TREATING HIF-1a OVER-EXPRESSING CANCERS - Described herein are compositions that include monoclonal antibodies that specifically bind Hsp90α and methods of using the same to treat HIF-1a-overexpressing cancer. In some embodiments, the cancers are breast cancer or lung cancer. The monoclonal antibodies bind the epitope TKPIWTRNP in Hsp90α or VKHFSVEGQ in Hsp90α. | 2016-02-25 |
20160053004 | NUCLEIC ACIDES ENCODING ANTI-C5A ANTIBODIES - The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease. | 2016-02-25 |
20160053005 | METHODS FOR DIAGNOSING AND TREATMENT OF BREAST CANCER AND PHARMACEUTICAL COMPOSITION AND KIT FOR SAME - Among other findings, the subject matter is based on the identification that p14 peptide is expressed in mammary carcinoma cells harboring MMTV. Thus, provided are methods for diagnosing breast cancer in subjects comprising determining the levels of expression of the peptide or the levels of anti-p14 antibodies produced in the subject to the peptide. Further provided are screening methods of individuals with high probability of having breast cancer as well as to therapeutic methods; pharmaceutical compositions and vaccine making use of the anti-p14 antibodies or p14 peptides or produced thereby. | 2016-02-25 |
20160053006 | COMPOSITIONS AND METHODS RELATING TO INHIBITING CANCER CELL GROWTH AND/OR PROLIFERATION - The present invention determined that EGFL6 functions as a tumor vascular regulator of ovarian cancer stem cells (CSC). In addition, the present invention determined that a novel EGFL6 blocking antibody was able to restrict cancer cell growth and delay disease recurrence. As such, the present invention provides compositions and methods for inhibiting cancer cell growth, proliferation and/or metastasis. In particular, the present invention provides methods for inhibiting cancer cell growth, proliferation and/or metastasis through administration of a composition comprising an agent capable of inhibiting the function of EGFL6 (e.g., thereby inhibiting related cancer cell growth). In some embodiments, the agent capable of inhibiting the function of EGFL6 is an EGFL6 blocking antibody. The agents and related compositions additionally find use in diagnostic and research settings | 2016-02-25 |
20160053007 | ANTIBODIES THAT BIND TO TL1A AND METHODS OF TREATING INFLAMMATORY OR AUTOIMMUNE DISEASE COMPRISING ADMINISTERING SUCH ANTIBODIES - Methods and compositions for treating inflammatory or autoimmune diseases in a subject comprising blocking the interaction between DR3 and TL1A. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a T cell component, including asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease. | 2016-02-25 |
20160053008 | ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F AND METHODS OF USING SAME - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation. | 2016-02-25 |
20160053009 | MELATONIN MONOCLONAL ANTIBODY, DETECTION, METHODS AND USES THEREOF - The invention provides monoclonal antibodies and fragments thereof that specifically bind to melatonin. Also provided are heavy chain variable region (VH) and light chain variable region (VL) sequences of such monoclonal antibodies and fragments thereof. Further provided are melatonin conjugates, and methods and uses, for example, determining, detecting, measuring, screening for, analyzing and monitoring an amount of melatonin in a sample. | 2016-02-25 |
20160053010 | IMMUNOLOGICAL COMPOSITIONS AS CANCER THERAPEUTICS - The present invention concerns antibodies that react immunologically with an epitope comprising VDKSRWQQG (SEQ ID NO: 1), including those that bind to cancer cells, and methods relating thereto. In particular, the antibodies that react immunologically with a particular epitope found in anti-tumor antigen antibodies are not only indicative of favorable therapy using the anti-tumor antigen antibodies, but are therapeutic in and of themselves. | 2016-02-25 |
20160053011 | ANTIBODY SPECIFICALLY BINDING TO HER2 - The present invention relates to HER2 (Human Epidermal Growth Factor Receptor 2) antibodies to prevent or treat cancers. The antibodies of the invention binds specifically to HER2 over-expressed in cancer cells (particularly, breast cancer and stomach cancer cells), specifically to an epitope on HER2 being different from epitope for trastuzumab. The CDR sequences of the present antibodies exhibit low similarity to CDR sequences of publicly known HER2 antibodies, addressing that the CDR sequences are unique. The antibodies of the present invention in combination with trastuzumab kill cancer cells with significantly enhanced cytotoxicity and therefore very effective in therapy of cancer (particularly, breast cancer and stomach cancer). Without wishing to be bound by theory, the enhanced efficacies of the combined therapy would address that the antibodies of the present invention bind to epitope on HER2 being different from epitope for trastuzumab, and inhibit HER2 in a cooperative manner with trastuzumab. | 2016-02-25 |
20160053012 | COMPOSITIONS AND METHODS FOR PRESERVING CELLS OF THE EYE - The invention provides a method of preserving ocular cells in a patient having or at risk of developing glaucoma. In particular, microglial cell activation can be decreased, oligodendrocyte loss can be reduced, and/or the viability of retinal ganglion cells can be preserved by administering a selective TNFR2 antagonist to an individual having or at risk of developing glaucoma. | 2016-02-25 |
20160053013 | Antigen Binding Proteins that Bind CXCR3 - There is disclosed compositions and methods relating to or derived from anti-CXCR3 antibodies. More specifically, there is disclosed fully human antibodies that bind CXCR3, CXCR3-binding fragments and derivatives of such antibodies, and CXCR3-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having CXCR3 related disorders or conditions, including various inflammatory disorders and various cancers. | 2016-02-25 |
20160053014 | Antigen Binding Proteins that Bind CXCR5 - There is disclosed compositions and methods relating to or derived from anti-CXCR5 antibodies. More specifically, there is disclosed fully human antibodies that bind CXCR5, CXCR5-binding fragments and derivatives of such antibodies, and CXCR5-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having CXCR5 related disorders or conditions, including various inflammatory disorders and various cancers. | 2016-02-25 |
20160053015 | ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF - The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2016-02-25 |
20160053016 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER - The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells. | 2016-02-25 |
20160053017 | ANTI-CD276 POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS - Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed. | 2016-02-25 |
20160053018 | ANTI-HUMAN TROP-2 ANTIBODY HAVING ANTI-TUMOR ACTIVITY IN VIVO - The present invention provides: an antibody, which specifically reacts with hTROP-2 and has anti-tumor activity in vivo; a hybridoma, which produces the aforementioned antibody; a complex of the aforementioned antibody and a drug; a pharmaceutical composition for diagnosing or treating a tumor; a method for detecting a tumor; and a kit for detecting or diagnosing a tumor. | 2016-02-25 |
20160053019 | MONOCLONAL ANTIBODY CAPABLE OF BINDING TO ANEXELEKTO, AND USE THEREOF - The present inventors have succeeded in producing anti-AXL antibodies with specific functions. The present inventors also discovered that the antibodies have an angiogenesis-suppressive effect and an antitumor effect, and thereby completed the present invention. The anti-AXL antibodies of the present invention are useful as angiogenesis inhibitors and agents for inducing or inhibiting phosphorylation activity. | 2016-02-25 |
20160053020 | HUMAN ANTIBODIES AGAINST TISSUE FACTOR AND METHODS OF USE THEREOF - Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies. | 2016-02-25 |
20160053021 | Regulating Transplant Rejection of Donor and Embryonic Stem Cell-Derived Tissues and Organs - The invention provides methods and cells for improved transplantation of donor transplants to subjects in need thereof. | 2016-02-25 |
20160053022 | ANTIBODIES AGAINST HUMAN RYK AND USES THEREFOR - The present invention relates to antibodies and antigen-binding fragments thereof that bind RYK, in particular human RYK and their use in regulating RYK-associated activities. Specifically there is provided an isolated monoclonal antibody or antigen-binding fragment or derivative thereof that specifically binds to the extracellular domain of human RYK, in particular, the antibody or antigen-binding fragment thereof, binds specifically to the WIF domain of human RYK. Preferably, the antibodies of the present invention modulate RYK-associated activity, which includes RYK mediated signal transduction activity and modulation of the interaction of Wnts with RYK and, preferably, modulate Wnt induced signaling. In particular, the antibodies inhibit the binding of Wnt5a and inhibit Wnt induced phosphorylation of Dishevelled (Dvl) 2 and/or Dvl3 proteins. | 2016-02-25 |
20160053023 | METHODS OF TREATMENT FOR NEUROMYELITIS OPTICA - The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating neuromyelitis optica (NMO) and, more specifically, to methods involving the inhibition of the classical pathway of complement activation. | 2016-02-25 |
20160053024 | Bruton's Tyrosine Kinase As Anti-Cancer Drug Target - Receptor protein kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets. A large-scale loss-of-function analysis of tyrosine kinases using RNA interference in the clinically relevant Erb-B2 positive, BT474 breast cancer cell line showed that Bruton's tyrosine kinase (BTK), a cytosolic, non-receptor tyrosine kinase that has been extensively studied for its role in B cell development, is required, in altered form, for BT474 breast cancer survival. This alternative form contains an amino-terminal extension that is also present in tumorigenic breast cells at significantly higher levels than in normal breast cells. | 2016-02-25 |
20160053025 | ANTI-C-MET/ANTI-ANG2 BISPECIFIC ANTIBODY - An anti-c-Met/anti-Ang2 bispecific antibody including (a) an anti-c-Met antibody or antigen-binding fragment thereof and (b) an anti-Ang2 antibody or antigen-binding fragment thereof, a pharmaceutical composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method using the anti-c-Met/anti-Ang2 bispecific antibody. | 2016-02-25 |
20160053026 | METHODS FOR TREATING INFECTION BY HPV - We describe herein methods for treating HPV infections and medical conditions caused by HPV infections. Generally, the methods include administering to a subject exhibiting at least one symptom or clinical sign of HPV infection a composition that includes an EGFR signaling inhibitor in an amount effective to ameliorate the at least one symptom or clinical sign of HPV infection. | 2016-02-25 |
20160053027 | THERMALLY MODIFIED STARCH - A process for producing thermally inhibited starch is described resulting in a visco-stable starch product with improved whiteness. The process comprises pretreating a dry starch with an alkaline solution in a water-miscible solvent, adjusting the water content of the starch to below 12 wt. %, heating the starch at a temperature between 140 and 190° C., preferably between 140 and 180° C., and cooling and optionally further processing the starch. The thermally inhibited starch has the advantages of not being chemically modified. The process is more flexible and faster than conventional inhibition processes. | 2016-02-25 |
20160053028 | MEDIUM ADDITIVE FOR CELL CULTURE - Provided are a composition for enhanced production of a useful substance in cells containing a polysaccharide, a medium for cell culture containing a polysaccharide, and a process for preparing a useful substance including culturing cells in a medium for cell culture containing a polysaccharide. | 2016-02-25 |
20160053029 | ETHYLSULFONATED HYALURONIC ACID BIOPOLYMERS AND METHODS OF USE THEREOF - The present disclosure provides methods for sulfonation of hyaluronic acid. The present disclosure provides sulfonated hyaluronic acid, and compositions, including pharmaceutical compositions, comprising the sulfonated hyaluronic acid. The present disclosure provides implantable materials and drug delivery compositions comprising a subject sulfonated hyaluronic acid. | 2016-02-25 |
20160053030 | POLYMERISATION PROCESS - The present invention relates to a polymerisation process, in particular to the polymerisation of olefins in a reactor system comprising two reactors in series, and most particularly provides a process for the polymerisation of monomer in at least first and second reactors operated in series, which process comprises contacting a first stream comprising vapour derived from the effluent withdrawn from the second reactor with a feed stream to the second reactor, said feed stream comprising effluent derived from the first reactor. | 2016-02-25 |
20160053031 | NON-CYCLOPENTADIENYL-BASED CHROMIUM CATALYSTS FOR OLEFIN POLYMERIZATION - Provided is a non-cyclopentadienyl-based chromium-ligand complex, preferably a chromium-ligand complex of formula (J): LCr(R | 2016-02-25 |
20160053032 | COMPOUND, RESIN, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN - A resist composition has a resin (A1) including a structural unit having an acid-labile group, a resin (A2) including a structural unit having a group represented by formula (Ia), and an acid generator. | 2016-02-25 |
20160053033 | METHOD OF PRODUCTION OF RADIAL CONJUGATED DIENE RUBBER - A method of production of radial conjugated diene rubber including a first step of causing 65 to 500 moles of isoprene to polymerize, in the presence of an alkali metal-reacted aromatic compound which is represented by the following general formula (1), with respect to 1 mole of an alkali metal in the alkali metal-reacted aromatic compound so as to obtain a radial isoprene polymer which has active ends and a second step of causing monomers which contain 1,3-butadiene or 1,3-butadiene and an aromatic vinyl compound to polymerize to the active ends of the radial isoprene polymer is provided. | 2016-02-25 |
20160053034 | POLYPROPYLENE COMPOSITION WITH IMPROVED IMPACT RESISTANCE FOR PIPE APPLICATIONS - The present invention relates to a polypropylene composition comprising a multimodal propylene random copolymer with at least one comonomer selected from alpha-olefins with 2 or 4 to 8 carbon atoms, wherein the polypropylene composition has a melt flow rate MFR | 2016-02-25 |
20160053035 | Polymers With Improved ESCR for Blow Molding Applications - Disclosed herein are ethylene-based polymers having a higher molecular weight component and a lower molecular weight component, and characterized by a density greater than 0.945 g/cm | 2016-02-25 |
20160053036 | RESIN COMPOSITION CONTAINING ETHYLENE-VINYL ALCOHOL COPOLYMER - The present invention provides a resin composition containing (A) an ethylene-vinyl alcohol copolymer and (B) an unsaturated aldehyde (B), in which the content of the unsaturated aldehyde (B) with respect to the resin composition containing the ethylene-vinyl alcohol copolymer is 0.01 ppm or more and 100 ppm or less. The unsaturated aldehyde (B) is preferably crotonaldehyde, 2,4-hexadienal, 2,4,6-octatrienal or a combination thereof. In addition, it is preferred that the resin composition further contains a boron compound, and the content of the boron compound is 100 ppm or more and 5,000 ppm or less. Also, it is preferred that the resin composition further contains a conjugated polyene compound, and the content of the conjugated polyene compound is 0.01 ppm or more and 1,000 ppm or less. | 2016-02-25 |
20160053037 | SUPER ABSORBENT POLYMER AND PREPARATION METHOD THEREOF - The present invention relates to a super absorbent polymer and a preparation method thereof, the super absorbent polymer including: surface cross-linked polymer particles prepared by surface cross-linking particles of a base resin, the base resin polymerized from a monomer composition including water-soluble ethylene-based unsaturated monomers having at least partially neutralized acidic groups; and a water-soluble component, wherein the water-soluble component has a weight average molecular weight of 150,000 to 300,000 g/mol. The super absorbent polymer may have high centrifuge retention capacity and excellent permeability at the same time, while having low content of the water-soluble component. | 2016-02-25 |
20160053038 | HYDROPHILIZED BACTERICIDAL POLYMERS - A bactericidal polymeric composition includes a hydrophilic first comonomer copolymerized to a second comonomer to produce a polymeric composition that is more hydrophilic or more bactericidal in an aqueous solution than either of the comonomers alone. Methods for identifying bactericidal polymers, methods for rendering materials bactericidal, and methods for using bactericidal compositions to kill or reduce bacterial growth are also described. Applications for the inventive compositions include their use in catheters, stents, medical devices, contact lenses; root canal fillers; and/or wound dressings. | 2016-02-25 |
20160053039 | BINDER FOR MANUFACTURING INORGANIC SINTERED BODY - The present invention provides a binder for manufacturing an inorganic sintered body that has excellent adhesiveness upon heat pressing and thermal decomposability and, especially when used as a binder for a ceramic green sheet, provides a ceramic green sheet having sufficient mechanical strength and flexibility. The present invention also provides a paste for manufacturing an inorganic sintered body, a ceramic green sheet, and a ceramic laminate individually manufactured using the binder for manufacturing an inorganic sintered body. The present invention provides a binder for manufacturing an inorganic sintered body containing a graft copolymer having a unit including polyvinyl butyral and a unit including a poly(meth)acrylic compound, the polyvinyl butyral having a polymerization degree of 800 to 5000, a hydroxy group content of 20 to 40 mol %, and a butyralization degree of 60 to 80 mol %, the unit including a poly(meth)acrylic compound having a glass transition temperature of 0 to 110° C. | 2016-02-25 |
20160053040 | REINFORCING AGENT FOR POLYCARBONATE RESIN, POLYCARBONATE RESIN COMPOSITION, AND MOLDED ARTICLE - [Object] Provided is a reinforcing agent for resin that is able to impart excellent impact resistance, resistance to thermal coloration, and resistance to moist heat to a polycarbonate resin. | 2016-02-25 |
20160053041 | POLYSTYRENE-POLYACRYLATE BLOCK COPOLYMERS, METHODS OF MANUFACTURE THEREOF AND ARTICLES COMPRISING THE SAME - Disclosed herein is a block copolymer comprising a first block derived from a vinyl aromatic monomer; and a second block derived from an acrylate monomer; where a chi parameter that measures interactions between the first block and the second block is greater than or equal to about 0.05, when measured at 240° C. Disclosed herein too is a method comprising polymerizing a vinyl aromatic monomer to form a first block; and polymerizing a second block onto the first block to form a block copolymer; where the second block is derived by polymerizing an acrylate monomer; and where the block copolymer has a chi parameter of greater than or equal to about 0.05, when measured at 240° C.; where the chi parameter is a measure of interactions between the first block and the second block. | 2016-02-25 |
20160053042 | Modified Polyaryletherketone Polymer (Paek) and Process To Obtain It - The present invention relates to a modified polyaryletherketone polymer (PAEK) with chemically modified surfaces with azides, alkynes, thiols, maleimides, sulfonylazides or thio acids, suitable for “click” reactions and to a process to obtain it. It also relates to the conjugated biomaterials derived thereof, PAEK type materials with surfaces modified with a RGD (Arg-Gly-Asp) and/or OGP | 2016-02-25 |
20160053043 | CURING COMPOSITIONS AND METHODS OF PREPARING - Disclosed are curing compositions for resin systems and in particular for phenolic resin systems and epoxy resin systems, to methods of preparing the curing compositions and to resin systems incorporating same. The curing compositions of the invention are the reaction product of an aldehyde with an amine in the presence of an aprotic solvent. | 2016-02-25 |
20160053044 | POLYTHIOURETHANE-BASED CASTING RESIN HAVING HIGH FRACTURE RESISTANCE AND LOW SPECIFIC WEIGHT - The invention has as subject matter a method for producing a polyurethane cast resin, wherein the production comprises the steps of mixing at least one thiol component with at least one isocyanate component, degassing of the mixture and hardening of the polyurethane polymer in a one-stage process. Cast resins for electronic or optoelectronic components of for the production of optical lenses are obtained by the method of the invention that have good mechanical properties and very good optical properties at the same time by a suitable combination of polythiols as hardening component with commercially available isocyanates. The addition of special isocyanates is also not very necessary, as is the case for carrying out the method in several stages. The method in accordance with the invention results in an economical, one-stage process in the properties of the cast resin that are necessary for the application range. | 2016-02-25 |
20160053045 | MULTIPLE ACCELERATOR SYSTEMS FOR EPOXY ADHESIVES - There is provided a one -part curable epoxy composition comprising a heat curable epoxy resin; and a latent curative system in an amount sufficient to cure the epoxy resin, where the latent curative system comprises at least one epoxy resin miscible first curative comprising a latent hardener, selected from dicyandiamide and its derivatives, and two or more latent accelerators selected from at least one of substituted ureas, substituted imidazoles, and combinations thereof. There are also provided adhesive compositions, cured adhesives and articles made using such one-part curable epoxy compositions. | 2016-02-25 |
20160053046 | HARDENERS FOR COLD-CURING EPOXY SYSTEMS - A hardener composition comprising: a) an isolated adduct comprising a reaction product of i) a polymer with a functionality of at least three, wherein said polymer contains at least one epoxy group; and ii) an amine wherein the isolated adduct is present as an aqueous solution; and b) a capping agent. This hardener can be used with a liquid epoxy resin to form a curable composition. | 2016-02-25 |
20160053047 | PROCESSING BIOMASS - Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful intermediates and products, such as amino-alpha, omega-dicarboxylic acid and amino-alpha, omega-dicarboxylic acid derivatives. These products include polymers and copolymers of alpha-amino, omega-dicarboxylic acids. | 2016-02-25 |
20160053048 | CATALYST FOR POLY(LACTIDE) SYNTHESIS AND USES THEREOF - Catalysts for poly(lactide) synthesis are provided herein. Also provided are methods of synthesizing the catalysts, methods of using the catalysts to make poly(lactides), and compositions comprising the same. | 2016-02-25 |